Risk of stroke with thiazolidinediones: A ten-year nationwide population-based cohort study

Cerebrovascular Diseases

Volumn 36, Issue 2, 2013, Pages 145-151

  Lu, Chien Jung ^a   Sun, Yu ^a   Muo, Chih Hsin ^c   Chen, Rong Chi ^a   Chen, Pei Chun ^b   Hsu, Chung Y ^d  

^a EN CHU KONG HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cohort; Diabetes; Ischemic stroke; Pioglitazone; Rosiglitazone; Thiazolidinedione

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ASIAN; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; ETHNICITY; FOLLOW UP; INSULIN TREATMENT; LOW DRUG DOSE; TAIWAN; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RISK; STROKE; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 84885644483     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000353679     Document Type: Article

References (29)

1. Rodriguez-Yanez M, Castellanos M, Blanco M, Mosquera E, Castillo J: Vascular protection in brain ischemia. Cerebrovasc Dis 2006; 21(suppl 2):21-29
2. White AT, Murphy AN: Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem 2010; 115: 845-853
3. Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK: Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009; 18: 437-447
4. Vanasse A, Carpentier AC, Courteau J, Asghari S: Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res 2009; 6: 87-93
5. Azoulay L, Schneider-Lindner V, Dell?aniello S, Filion KB, Suissa S: Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 343-350
6. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195
7. Shaya FT, Lu Z, Sohn K, Weir MR: Thiazolidinediones and cardiovascular events in highrisk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. PT 2009; 34: 490-501
8. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH: Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121: 1868-1877
9. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471
10. Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D: Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther 2008; 15: 506-511
11. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta- analysis of randomized trials. JAMA 2007; 298: 1180-1188
12. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418
13. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW: Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009; 32: 675-690
14. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873
15. Lu JF, Hsiao WC: Does universal health insurance make health care unaffordable Lessons from Taiwan. Health Aff (Millwood) 2003; 22: 77-88
16. NHI profile (updated June 5, 2009). Available at http://www.nhi.gov.tw/ webdata/AttachFiles/Attach-13787-1-NationalHealthInsurance inTaiwan2009.pdf (accessed September 4, 2010)
17. National Health Research database. Available at http://w3.nhri.org.tw/ nhird/en/Data-Sub sets.html#S3 (accessed September 14, 2010)
18. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
19. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD: Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824-831
20. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, Mc- Murray JJ: Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007; 357: 28-38
21. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH: Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168: 2368-2375
22. Diamond GA, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578-581
23. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH: Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007:CD006063
24. Margolis DJ, Hoffstad O, Strom BL: Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17: 753-759
25. Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H: Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol 2011; 51: 173-180
26. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM: Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population-based cohort study. BMJ 2009; 339:b2942
27. Hsiao A, Worrall DS, Olefsky JM, Subramaniam S: Variance-modeled posterior inference of microarray data: detecting gene expression changes in 3T3-L1 adipocytes. Bioinformatics 2004; 20: 3108-3127
28. Stafylas PC, Sarafidis PA, Lasaridis AN: The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009; 131: 298-304
29. Gil-Nunez A: The metabolic syndrome and cerebrovascular disease: suspicion and evidence. Cerebrovasc Dis 2007; 24(suppl 1):64-75